推荐产品
應用
Complement C9 from human serum is an essential part of the terminal complement system. It has been a topic in cancer research, where extracellular phosphorylation by ecto-PK of K562 cells on serine residues may serve as a protective mechanism against complement in tumor cells. Additionally, it can be used as a biomarker (in fucosylated form) for squamous cell lung cancer, as patients tend to show elevated levels of C9 protein.
生化／生理作用
Complement component C9 is the final component of the membrane attack complex (MAC) responsible for cell lysis by complement. CD59 binds to both C8 and C9 and prevents assembly of an active MAC, protecting cells against lytic activity.
品質
Functionally pure by a sensitive hemolytic assay using deficient sera.
外觀
Supplied as a solution in phosphate buffered saline, pH 7.2.
其他說明
View more information on the complement pathway at www.sigma-aldrich.com/enzymeexplorer
免責聲明
RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.
儲存類別代碼
10 - Combustible liquids
閃點（°F）
Not applicable
閃點（°C）
Not applicable
Y Paas et al.
Archives of biochemistry and biophysics, 316(2), 780-788 (1995-02-01)
Ecto-protein kinases (ecto-PK), primarily of the serine/threonine kinase type, have been previously described on the surface of various normal, transformed, and tumor cells. We have found that in the presence of ATP and Mg2+, exogenously added substrates such as phosvitin
Phosphorylation of the complement component, C9, by an ecto-protein kinase of human leukemic cells
Paasa, Y., et al.
Immunopharmacology and Immunotoxicology, 42, 175-785 (1999)
Yoshimitsu Kuwabara et al.
PloS one, 13(6), e0198472-e0198472 (2018-06-13)
Immunoproteomic analysis was performed to identify unknown, pathology-related molecules in patients with seronegative (SN) obstetric antiphospholipid syndrome (APS) who clinically satisfied the diagnostic criteria for APS, but not the serological criteria. We collected peripheral blood from 13 SN-APS outpatients with
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门